NTLX Neurothera Labs Inc.

2.796USD4.000 CAD · TSXV0.00%Mkt Cap: 237.40M USDP/E: —

Neurothera Labs Inc. engages in the development of a portfolio of drugs based on cannabinoid molecules. The company develops programs based on tetrahydrocannabinol (THC) and/or non-psychoactive cannabidiol for the treatm…

Key Statistics

Company
Market Cap237.40M USD
Enterprise Value41.38M USD
Revenue (TTM)680.00K USD
Gross Profit631.00K USD
Net Income (TTM)-4.12M USD
Revenue/Share0.12 USD
Last Price2.796 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - General
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-16.16
EV/Revenue60.85
P/S499.41
P/B9.40
EPS (TTM)-1.19 USD
EPS (Forward)—
52W Range
1.12564% of range3.719
52W High3.719 USD
52W Low1.125 USD
Profitability
Gross Margin73.71%
Oper. Margin-565.44%
EBITDA Margin0.00%
Profit Margin-481.66%
ROE-3076.87%
ROA-135.94%
ROIC—
ROCE-250.57%
Growth
Revenue Growth-38.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.66M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt7.00K USD
Net Debt/EBITDA-0.00
Net Debt/FCF—
Balance Sheet
Debt/Equity6.97
Current Ratio0.25
Quick Ratio0.23
Book Value/Sh0.43 USD
Cash/Share0.07 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:14
Split DateSep 2, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.84.90M
Float7.54M
Insiders33.34%
Institutions0.00%
Short Interest
Short Ratio0.8d
Short % Out.0.00%
Shares Short60
Short (prev mo.)222
Technical
SMA 502.172 (+28.8%)
SMA 2002.076 (+34.7%)
Beta-0.12
S&P 52W Chg12.00%
Avg Vol (30d)2.35K
Avg Vol (10d)6.86K
Technical Indicators
RSI (14)70.5
MACD0.0787
MACD Signal-0.2755
MACD Hist.+0.3542
BB Upper2.827 USD
BB Middle1.547 USD
BB Lower0.2675 USD
BB Width165.43%
ATR (14)0.1867 USD
Vol Ratio (20d)6.50x

About Neurothera Labs (CVE: NTLX)

›

Neurothera Labs (CVE: NTLX) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector.

The shares were at 4.000 CAD on 18 November 2026, up 90.5% over 52 weeks. Its 52-week range is 1.610 CAD to 5.320 CAD: the price is 24.8% below the high and 148.4% above the low.

Its market capitalisation is 339.60M CAD.

Neurothera Labs reports revenue down 38.2% year over year.

Its debt exceeds its cash by 7.00K USD, a debt-to-equity ratio of 6.97. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 28 January 2027.